Optimierte Therapie für Kreuzbandverletzungen

Forschende des Fraunhofer-Instituts für Digitale Medizin MEVIS, des Universitätsklinikums Freiburg und der Stryker Leibinger GmbH & Co. KG sind für ihre Publikation „Validierung einer Finite-Elemente-Simulation zur Vorhersage der individuellen Kniegelenkskinematik“ mit dem Forschungspreis Digitalisierung in Orthopädie und Unfallchirurgie 2024 ausgezeichnet worden. Die Preisverleihung fand am 25. Oktober 2024 auf dem Deutschen Kongress für Orthopädie und Unfallchirurgie (DKOU 2024) in Berlin statt.

### Background Research for the Article

Kreuzbandverletzungen, commonly known as ACL (anterior cruciate ligament) injuries, are among the most frequently occurring knee injuries in athletes and active individuals. The anterior cruciate ligament is essential for maintaining stability in the knee joint. ACL injuries can happen due to various reasons, including sudden stops, changes in direction while running or jumping.

These injuries often require complex treatment options ranging from physical therapy to surgical intervention. The recovery process can be lengthy and challenging, making advancements in therapeutic approaches crucial for improving outcomes for patients.

The collaboration between research institutes like Fraunhofer MEVIS, clinical hospitals such as Universitätsklinikum Freiburg, and medical technology companies like Stryker Leibinger GmbH & Co. KG reflects a multidimensional approach toward enhancing orthopedic care through innovative technology—specifically finite element simulations.

Finite element analysis (FEA) is a computational technique that can be used to predict how structures respond to external forces by breaking down complex shapes into smaller elements that are easier to analyze mathematically. In this case, it allows researchers and clinicians alike to understand the biomechanical behavior of individual knees under varying conditions.

By focusing on individualized predictions of knee joint kinematics—how the kneecap moves during specific actions—the team has made significant strides toward improving rehabilitation protocols and pre-surgical planning specific to each patient’s needs. This kind of personalized medicine aims not only at providing targeted treatments but also streamlining recovery journeys.

Their recent work earned them the 2024 Forschungspreis Digitalisierung in Orthopädie und Unfallchirurgie (Research Award for Digitalization in Orthopedics and Trauma Surgery), highlighting its importance within both academic research circles and practical applications within health services.

### Frequently Asked Questions (FAQ)

**Q1: What is an ACL injury?**
**A1:** An ACL injury refers specifically to damage or rupture of the anterior cruciate ligament located in your knee joint. This type of injury usually results from sports-related activities involving sudden stops or changes in direction.

**Q2: Who collaborated on this research?**
**A2:** The study was a collaborative effort among researchers from Fraunhofer-Institut für Digitale Medizin MEVIS, Universitätsklinik Freiburg’s medical team members specializing primarily in orthopedics along with experts from Stryker Leibinger GmbH & Co. KG—a company known for medical technology solutions.

**Q3: What does “finite-element simulation” mean?**
**A3:** Finite-element simulation is a computational method used by engineers and scientists across various fields (including biomechanics) where structures are broken down into smaller parts called „elements“ allowing extensive analysis regarding how materials react when exposed certain conditions like force or pressure during movement.

**Q4: How does finite-element simulation benefit treatment plans?**
**A4:** By analyzing individual knee kinematics through simulations tailored specifically per patient’s anatomy/functionality will enable doctors/therapists devise rehab programs more suited towards speeding up their patients‘ healing times whilst reducing possible complications arising post-injury/surgery phase ensuring overall quality-of-life improvement thereafter!

**Q5: Why was their publication recognized with an award?**
**A5:** Their publication was honored because it represents groundbreaking work integrating advanced technologies which revolutionize traditional methods applied upon treating critical orthopedic cases thus advancing practical applications benefiting societies’ healthcare systems immensely!

This comprehensive understanding should help clarify any queries about this essential new advancement targeting better rehabilitation techniques after major sports-related injuries; showcasing innovation meeting patient-centered care perfectly!

Originamitteilung:

Forschende des Fraunhofer-Instituts für Digitale Medizin MEVIS, des Universitätsklinikums Freiburg und der Stryker Leibinger GmbH & Co. KG sind für ihre Publikation „Validierung einer Finite-Elemente-Simulation zur Vorhersage der individuellen Kniegelenkskinematik“ mit dem Forschungspreis Digitalisierung in Orthopädie und Unfallchirurgie 2024 ausgezeichnet worden. Die Preisverleihung fand am 25. Oktober 2024 auf dem Deutschen Kongress für Orthopädie und Unfallchirurgie (DKOU 2024) in Berlin statt.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

Optimized Therapy for Cruciate Ligament Injuries

Researchers from the Fraunhofer Institute for Digital Medicine MEVIS, the University Medical Center Freiburg, and Stryker Leibinger GmbH & Co. KG have been awarded the Research Prize for Digitalization in Orthopedics and Trauma Surgery 2024 for their publication entitled “Validation of a Finite Element Simulation for Predicting Individual Knee Joint Kinematics.” The award ceremony took place on October 25, 2024, during the German Congress for Orthopedics and Trauma Surgery (DKOU 2024) in Berlin.

Read More

Studienergebnissen von Bruton-Tyrosinkinase-Inhibitoren zur Behandlung der Multiplen Sklerose

29.10.2024 – Bruton-Tyrosinkinase-Inhibitoren (BTKi) werden aktuell für die Behandlung verschiedener Autoimmunerkrankungen entwickelt, insbesondere für Multiple Sklerose (MS). Die beiden Präparate Evobrutinib und Tolebrutinib konnten in der schubförmigen MS keine Überlegenheit gegenüber Teriflunomid zeigen. Allerdings liegen nun erstmals positive Studienergebnisse für Tolebrutinib für die Therapie der sekundär-progredienten MS ohne Schübe vor, die Hoffnung bei MS-Betroffenen wecken. Der mögliche Nutzen und die potentiellen Risiken dieser neuen Substanzklasse sollen hier erläutert werden.

Read More